title: The impact of pulmonary Acinetobacter baumannii infection on the prognosis of inpatients in a neurological intensive care unit.
abstract: OBJECTIVE
  To investigate the impact of pulmonary Acinetobacter baumannii infection on the prognosis of patients in a Chinese neurological intensive care unit (NICU).
  
  
  METHODS
  Patients with pulmonary infection and positive sputum culture findings were retrospectively enrolled. Logistic regression analysis was used to determine the factors influencing prognosis. Neurological disease improvement/nonimprovement and mortality rates were assessed.
  
  
  RESULTS
  The study included 374 NICU patients with pulmonary infection (110 [29.4%] with A. baumannii, 264 [70.6%] with other micro-organisms). A. baumannii infection (OR = 2.987) and invasive mechanical ventilation (OR = 16.898) were independent factors in disease prognosis. A. baumannii infection was associated with longer NICU stay, fewer improved patients and increased mortality rate compared with other pulmonary infections.
  
  
  CONCLUSIONS
  A. baumannii infection prolongs the duration of the NICU stay and negatively impacts on prognosis. Prognosis of NICU patients could be improved by controlling A. baumannii infection.
authors.affiliation: Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing China.
authors.forename: Yong-xiang
authors.initials: YX
authors.lastname: Mao
authors.forename: Guang-wei
authors.initials: GW
authors.lastname: Liu
authors.forename: Liang
authors.initials: L
authors.lastname: Wang
authors.forename: Xue-feng
authors.initials: XF
authors.lastname: Wang
authors.forename: Feng
authors.initials: F
authors.lastname: Li
mesh_terms: D000151:Acinetobacter Infections / Q000150:complications / Q000382:microbiology* / Q000401:mortality / Q000628:therapy; D040981:Acinetobacter baumannii / Q000187:drug effects / Q000254:growth & development; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000150:complications / Q000382:microbiology* / Q000401:mortality / Q000628:therapy; D005260:Female; D006801:Humans; D007297:Inpatients; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D019636:Neurodegenerative Diseases / Q000150:complications / Q000382:microbiology* / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D012121:Respiration, Artificial; D012141:Respiratory Tract Infections / Q000150:complications / Q000382:microbiology* / Q000401:mortality / Q000628:therapy; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D000900:Anti-Bacterial Agents
keywords: Acinetobacter baumannii; disease development; intensive care unit; pulmonary infection